Scholarlink

Background <p>Activated leukocyte cell adhesion molecule (ALCAM) serves as an important effector that activates and traffics lymphocytes into tissues. The expression and role of ALCAM in IgA nephropathy (IgAN) remain unclear. Here, we aim to evaluate the expression and effect of ALCAM in IgAN patients.</p> Methods <p>We performed a prospective study including 71 IgAN patients, and 41 controls. Serum and uALCAM levels were evaluated. Renal expression of ALCAM and its ligand S100B were measured. The correlation of serum ALCAM with clinical data, renal pathology, and prognosis was analyzed. Cox regression analysis was conducted to identify independent factors associated with prognosis. Kaplan-Meier survival analysis was performed to explore the role of serum ALCAM.</p> Results <p>Circulating ALCAM levels were higher in IgAN patients than in controls. Serum ALCAM levels showed a positive correlation with proteinuria and renal pathology. Renal ALCAM expression was also elevated in IgAN patients. IgAN patients were divided into low and high ALCAM groups (&lt; 4.76, and ≥ 4.76 ng/mL) based on the optimal cut-off value for predicting renal progression. The high ALCAM group exhibited more severe clinical parameters and renal pathology. High serum ALCAM level was an independent risk factor for IgAN progression. IgAN patients with high ALCAM level exhibited a lower cumulative renal survival rate compared to the low-level group.</p> Conclusions <p>In summary, serum ALCAM level in IgAN patients was elevated, which was consistent with clinical and pathological severity, and served as an independent risk factor and a promising novel predictor for the progression of IgAN.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Zengyuan Luo,
  • Linlin Zhang,
  • Zaiyu Wang,
  • Qi Xiong,
  • Jieyu Tang,
  • Yongwen Yang,
  • Xueling Hu,
  • Huipeng Ge,
  • Xiangcheng Xiao,
  • Rong Tang,
  • Wei Lin

摘要

Background

Activated leukocyte cell adhesion molecule (ALCAM) serves as an important effector that activates and traffics lymphocytes into tissues. The expression and role of ALCAM in IgA nephropathy (IgAN) remain unclear. Here, we aim to evaluate the expression and effect of ALCAM in IgAN patients.

Methods

We performed a prospective study including 71 IgAN patients, and 41 controls. Serum and uALCAM levels were evaluated. Renal expression of ALCAM and its ligand S100B were measured. The correlation of serum ALCAM with clinical data, renal pathology, and prognosis was analyzed. Cox regression analysis was conducted to identify independent factors associated with prognosis. Kaplan-Meier survival analysis was performed to explore the role of serum ALCAM.

Results

Circulating ALCAM levels were higher in IgAN patients than in controls. Serum ALCAM levels showed a positive correlation with proteinuria and renal pathology. Renal ALCAM expression was also elevated in IgAN patients. IgAN patients were divided into low and high ALCAM groups (< 4.76, and ≥ 4.76 ng/mL) based on the optimal cut-off value for predicting renal progression. The high ALCAM group exhibited more severe clinical parameters and renal pathology. High serum ALCAM level was an independent risk factor for IgAN progression. IgAN patients with high ALCAM level exhibited a lower cumulative renal survival rate compared to the low-level group.

Conclusions

In summary, serum ALCAM level in IgAN patients was elevated, which was consistent with clinical and pathological severity, and served as an independent risk factor and a promising novel predictor for the progression of IgAN.

Clinical trial number

Not applicable.